We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Myriad Genetics: Q4 Hit by Low Test Revenues, Gross Margin
Read MoreHide Full Article
On Aug 16, we issued an updated research report on Salt Lake City, UT-based molecular diagnostics provider, Myriad Genetics, Inc. (MYGN - Free Report) . The company currently carries a Zacks Rank #4 (Sell).
Myriad ended fiscal 2016 on a disappointing note, with its fourth-quarter numbers missing the Zacks Consensus Estimate on both fronts. The revenue decline in hereditary cancer testing business, which missed management’s expectations, was the major deterrent in the fourth quarter.
Moreover, CMS has lately adopted a new coding set for diagnoses, commonly known as ICD-10-CM, which significantly expands the current coding set. Myriad fears that the company may have to incur considerable expense in implementing ICD-10-CM, and, in failure of its adequate implementation, Myriad’s business might suffer a setback.
The declining gross margin, on the account of more revenue from lower margin segments as well as price reductions associated with the full implementation of long-term contracts, also raised concerns.
On the brighter note, despite witnessing a decline in its hereditary cancer testing revenues, management is currently pursuing a number of initiatives to stabilize and grow this business segment. To do this, the company submitted data to NCCN on expanding indications in breast cancer and pancreatic cancer.
During the fiscal fourth quarter, Myriad successfully completed the conversion to myRisk among its targeted physicians and have made gene panel standard of care within the marketplace. Following this transition, Myriad has more than doubled its Variant Classification database and introduced innovative new algorithmic methodologies for Variant Classification that will ensure Myriad's tests remain the gold standard for accuracy in the years to come.
In terms of reimbursement, Myriad signed a preferred provider agreement with BMI Healthcare in the U.S., U.K.,which will offer coverage to Myriad's complete testing portfolio including EndoPredict, Prolaris, tumor BRACAnalysis and hereditary cancer testing, including myRisk and all legacy tests.
With respect to the EndoPredict test, the company has already achieved ASCO guidelines for it, which has led to coverage with Aetna and indications of coverage for Medicare. Going forward, Myriad is actively reaching out to additional payers and will announce its U.S. commercialization plans for this test consequent to its launch in the second half of fiscal 2017.
Stocks to Consider
Some better-ranked medical stocks worth mentioning are ANI Pharmaceuticals, Inc. (ANIP - Free Report) , Anika Therapeutics Inc. (ANIK - Free Report) and Heska Corporation . All these stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Myriad Genetics: Q4 Hit by Low Test Revenues, Gross Margin
On Aug 16, we issued an updated research report on Salt Lake City, UT-based molecular diagnostics provider, Myriad Genetics, Inc. (MYGN - Free Report) . The company currently carries a Zacks Rank #4 (Sell).
Myriad ended fiscal 2016 on a disappointing note, with its fourth-quarter numbers missing the Zacks Consensus Estimate on both fronts. The revenue decline in hereditary cancer testing business, which missed management’s expectations, was the major deterrent in the fourth quarter.
Moreover, CMS has lately adopted a new coding set for diagnoses, commonly known as ICD-10-CM, which significantly expands the current coding set. Myriad fears that the company may have to incur considerable expense in implementing ICD-10-CM, and, in failure of its adequate implementation, Myriad’s business might suffer a setback.
The declining gross margin, on the account of more revenue from lower margin segments as well as price reductions associated with the full implementation of long-term contracts, also raised concerns.
On the brighter note, despite witnessing a decline in its hereditary cancer testing revenues, management is currently pursuing a number of initiatives to stabilize and grow this business segment. To do this, the company submitted data to NCCN on expanding indications in breast cancer and pancreatic cancer.
During the fiscal fourth quarter, Myriad successfully completed the conversion to myRisk among its targeted physicians and have made gene panel standard of care within the marketplace. Following this transition, Myriad has more than doubled its Variant Classification database and introduced innovative new algorithmic methodologies for Variant Classification that will ensure Myriad's tests remain the gold standard for accuracy in the years to come.
In terms of reimbursement, Myriad signed a preferred provider agreement with BMI Healthcare in the U.S., U.K.,which will offer coverage to Myriad's complete testing portfolio including EndoPredict, Prolaris, tumor BRACAnalysis and hereditary cancer testing, including myRisk and all legacy tests.
With respect to the EndoPredict test, the company has already achieved ASCO guidelines for it, which has led to coverage with Aetna and indications of coverage for Medicare. Going forward, Myriad is actively reaching out to additional payers and will announce its U.S. commercialization plans for this test consequent to its launch in the second half of fiscal 2017.
Stocks to Consider
Some better-ranked medical stocks worth mentioning are ANI Pharmaceuticals, Inc. (ANIP - Free Report) , Anika Therapeutics Inc. (ANIK - Free Report) and Heska Corporation . All these stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>